Treating obesity: does antagonism of NPY fit the bill?

Abstract

In this issue of Cell Metabolism, Erondu et al., (2006) identify a selective neuropeptide Y5 receptor antagonist that, as predicted from rodent studies, results in weight loss when administered to overweight and obese human subjects. In a one-year randomized placebo-controlled clinical trial, the weight loss was modest; the results support the emerging concept that NPY acts via overlapping and redundant energy homeostasis pathways.

• Authors: Sadaf Farooqi
• Journal: Cell metabolism (Cell Metab) Vol. 4 Issue 4 Pg. 260-2 (Oct 2006) ISSN: 1550-4131 [Print] United States
• PMID: 17011498 (Publication Type: Comment, Journal Article)

Chemical References

• Anti-Obesity Agents
• Receptors, Neuropeptide Y
• neuropeptide Y5 receptor

Topics

• Administration, Oral
• Animals
• Anti-Obesity Agents (administration & dosage, pharmacology, therapeutic use)
• Body Weight
• Dose-Response Relationship, Drug
• Humans
• Models, Biological
• Obesity (drug therapy)
• Receptors, Neuropeptide Y (antagonists & inhibitors, metabolism)
• Structure-Activity Relationship